Menu
← Oncology Approval Tracker
FDA DECISION ·
Carmustine for Injection (Accord)
carmustine · Accord Healthcare
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Injectable carmustine for palliative treatment in specified primary or metastatic brain tumors and labeled combinations in multiple myeloma, relapsed or refractory Hodgkin lymphoma and relapsed or refractory non-Hodgkin lymphoma.
LAMPGEN ANALYSIS
Why it matters
The product approval covers established carmustine indications across solid and hematologic cancers.
What research teams should watch
Verify the disease-specific combination and product preparation before adopting the formulation.
PRIMARY RECORDS